Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)
A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)
Inflammation of a muscle or muscle tissue.
An enzyme that activates histidine with its specific transfer RNA. EC 6.1.1.21.
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.
A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins.
Contractile tissue that produces movement in animals.
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
Myoglobinuria is the presence of myoglobin, a protein found in muscle fibers, in the urine, which can occur due to muscle injury or disease, and may lead to acute kidney injury if excessive.
Experimental animal models for human AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM. They include GUILLAIN-BARRE SYNDROME (see NEURITIS, AUTOIMMUNE, EXPERIMENTAL); MYASTHENIA GRAVIS (see MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL); and MULTIPLE SCLEROSIS (see ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL).
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Presence of air in the mediastinal tissues due to leakage of air from the tracheobronchial tree, usually as a result of trauma.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence.

Fas and Fas ligand interaction induces apoptosis in inflammatory myopathies: CD4+ T cells cause muscle cell injury directly in polymyositis. (1/296)

OBJECTIVE: To investigate the involvement of the Fas/Fas ligand (Fas/FasL) system in the inflammatory myopathies. METHODS: Frozen muscle sections obtained from 7 patients with polymyositis (PM), 4 patients with dermatomyositis (DM), and 3 controls were studied by immunochemistry. Apoptosis was detected by DNA electrophoresis and in situ labeling using the TUNEL method. RESULTS: Fas was detected on muscle fibers and infiltrating mononuclear cells (MNC) in 6 PM patients and 2 DM patients. FasL was expressed mainly on CD4+ T cells and some CD8+ T cells, and on macrophages surrounding Fas-positive muscles in 4 PM patients and 1 DM patient. In 3 of the 5 patients with FasL-positive MNC, the TUNEL method showed that both invaded myonuclei and MNC underwent apoptosis. Chromosomal DNA from the muscle tissue of these patients showed ladder formation. CONCLUSION: Fas/FasL is involved in muscle cell apoptosis in at least 2 of the inflammatory myopathies, PM and DM. Although CD8+-mediated cytotoxicity is thought to be the main mechanism of muscle injury in PM, our data suggest that CD4+ T cells also directly cause muscle cell damage.  (+info)

Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease. (2/296)

Myasthenia gravis and polymyositis are each a rare manifestation of immune dysregulation in chronic graft-versus-host disease (cGVHD). We report a 4-year-old boy with idiopathic acquired aplastic anemia who developed myasthenia gravis 22 months and polymyositis 69 months after an allogeneic BMT (5/6 matched, MLC-nonreactive). The occurrence of both syndromes in one patient is unique. Autoimmune dysfunction may be associated with the development of cGVHD as demonstrated by the high incidence of prior aplastic anemia in BMT patients presenting with myasthenia gravis and polymyositis. Recognition of these neurologic manifestations is important in the diagnosis and treatment of cGVHD.  (+info)

Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. (3/296)

OBJECTIVE: Pneumonia due to Pneumocystis carinii has been increasingly reported in patients with connective tissue diseases, but the frequency of this complication is not known. We sought to determine the frequency of P carinii pneumonia (PCP) in patients with connective tissue diseases, and to determine the role that a hospital's acquired immunodeficiency syndrome (AIDS)-related experience may have in the diagnosis of PCP in these patients. METHODS: We used a state hospitalization registry to identify all patients with PCP and either rheumatoid arthritis, systemic lupus erythematosus, Wegener's granulomatosis, polymyositis, dermatomyositis, polyarteritis nodosa, or scleroderma who had an emergent or urgent hospitalization in California from 1983 to 1994. We compared patient and hospital characteristics between these patients and patients with connective tissue diseases hospitalized with other types of pneumonia. RESULTS: Two hundred twenty-three patients with connective tissue diseases were diagnosed with PCP in the 12-year study period. The frequency of PCP ranged from 89 cases/10,000 hospitalizations/year in patients with Wegener's granulomatosis to 2 cases/10,000 hospitalizations/year in patients with rheumatoid arthritis. Compared with 5,457 patients with connective tissue diseases and pneumonia due to other organisms, patients with PCP were more likely to be younger, to be male, to have private medical insurance, and to have systemic lupus erythematosus, Wegener's granulomatosis, inflammatory myopathy, or polyarteritis nodosa rather than rheumatoid arthritis, and were less likely to be African American. Hospital size, teaching status, urban/rural location, proportion of admissions due to AIDS or PCP, and proportion of patients with pneumonia undergoing bronchoscopy were each associated with the likelihood of diagnosis of PCP in univariate analyses, but only the number of patients with PCP being treated at a hospital (odds ratio [OR] 1.03 for each additional 10 cases/year, 95% confidence interval [95% CI] 1.01-1.05) was associated with the likelihood of diagnosis of PCP in multivariate analyses. Patients were also somewhat more likely to be diagnosed with PCP if there had previously been a case of PCP in a patient with a connective tissue disease at the same hospital (OR 135, 95% CI 0.98-1.85). In-hospital mortality was 45.7%, and was unrelated to hospital characteristics. CONCLUSION: PCP is an uncommon, but often fatal, occurrence in patients with connective tissue disease. A hospital's prior experience with patients with PCP is associated with the likelihood that this condition is diagnosed in patients with connective tissue diseases who present with pneumonia, suggesting that diagnostic suspicion is an important factor in the correct identification of affected patients.  (+info)

Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis. (4/296)

Anti-histone antibodies have been detected in the sera of patients with various autoimmune diseases. The existence of anti-histone antibodies in patients with polymyositis/dermatomyositis, however, has not been reported. We found anti-histone antibodies in eight (17%) of 46 sera from patients with polymyositis/dermatomyositis by an enzyme-linked immunosorbent assay. One serum was positive for both IgG anti-histone antibodies and IgM anti-histone antibodies. Six sera were positive only for IgG anti-histone antibodies. One serum was positive only for IgM anti-histone antibodies. An indirect immunofluorescence analysis using HEp-2 cells as the substrate showed that all sera positive for anti-histone antibodies produced homogeneous nuclear fluorescence. This immunofluorescence pattern disappeared after absorption of anti-histone activity with total histones. An immunoblotting analysis demonstrated that the anti-histone antibodies were predominantly directed against histone H1 in all seven sera with IgG anti-histone antibodies. Weak reactivity with H2B and H4 were also found in three sera from the patients with polymyositis/dermatomyositis. Sera from two patients with polymyositis/dermatomyositis displayed anti-H2A and H3 activity. One of the two sera showed IgM anti-histone antibodies in the enzyme-linked immunosorbent assay reacted with H1, H2A, H2B, H3, and H4, whereas the other serum reacted with no fractions of total histones. The activity of anti-histone antibodies disappeared in immunoblotting after absorption with total histones. All of the patients with anti-histone antibodies were free from lung fibrosis or internal malignancies. Thus, our data indicate that the presence of anti-histone antibodies is classified as one of the serologic abnormalities observed in polymyositis/dermatomyositis.  (+info)

HLA-DRB1 genes in 5 rheumatic disease multi-case families. (5/296)

OBJECTIVE: To detect HLA-DRB1 (DR1-10) alleles in 5 families with multi-case rheumatic diseases, and to study the possible influence of DRB1 genes in the pathogenesis of rheumatic diseases. METHODS: Sequence-Specific Primer PCR (PCR-SSP) method was used to examine HLA-DRB1 alleles. Totally 36 members of 5 families and 166 healthy people were involved in this study. The results were assessed by Chi-square test. RESULTS: The HLA-DRB1 allele frequency in the patients and their relatives was similar. No significant difference was found. But DR4 allele frequency in the patients (90.9%) and their relatives (68%) was much higher than that in normal controls (16.8%) and the difference was statistically significant (P < 0.0001). In family 4, two RA patients have different DRB1 alleles, while in family 5, two patients have the same DRB1 alleles, one developed SLE and the other developed RA. CONCLUSIONS: DR4 is closely related to rheumatoid arthritis. The nelatives of RA patients may be at greater risk to develop RA than individuals without family history. Some patients had the same DRB1 allele but developed different rheumatic diseases. This suggested that there might be some common pathways in genetic predisposing of rheumatic diseases. On the other hand, only a few patients with the same DRB1 allele developed rheumatic diseases during their life, so other factors besides DRB1 gene might also be involved in the pathogenesis of rheumatic diseases.  (+info)

Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. (6/296)

To examine if the muscle fibers in patients with inflammatory myopathies have the potential to behave as antigen presenting cells (APCs), we investigated the expression of costimulatory molecules BB-1, B7-1 (CD80), and B7-2 (CD86), and their counterreceptors, CD28 or CTLA-4 (CD152), in the muscle biopsies of patients with polymyositis (PM), PM associated with human immunodeficiency virus infection (HIV-PM), sporadic inclusion body myositis (s-IBM), dermatomyositis (DM), and normal or disease controls. The expression of the B7 family of molecules on the muscle fibers was limited to BB-1. In PM, HIV-PM, and s-IBM, but not the disease controls, the nonnecrotic, MHC-class I-expressing muscle fibers, invaded or not by CD8+ T cells, had prominent membrane expression of BB-1. Several of the BB-1-positive fibers bound strongly in a cell-to-cell contact with their CD28 or CTLA-4 ligands on the autoinvasive CD8+ T cells, as confirmed by confocal microscopy. By reverse transcription-polymerase chain reaction, the expression of CD28 and CTLA-4 was up-regulated in PM, HIV-PM, and s-IBM, but not the controls. Because the BB-1-positive fibers expressed MHC-class I antigen and bound to up-regulated counterreceptors CD28 and CTLA-4 on the autoinvasive CD8+ T cells only in PM, HIV-PM, and s-IBM, the BB-1 molecule in these diseases should have a functional role in antigen presentation and T cell differentiation. These findings complement recent studies and suggest that in PM, HIV-PM, and s-IBM the muscle fibers are not only targets of CD8+ cytotoxic T cells but may also behave as "professional" APC.  (+info)

Autoantibodies in connective tissue diseases: clinical significance and analysis of target autoantigens. (7/296)

Systemic connective tissue diseases are characterized by the production of a number of autoantibodies directed against various cellular constituents. These autoantibodies are closely associated with certain diseases and clinical manifestations, and are therefore useful for clinical practice such as to diagnose diseases and to predict clinical subsets, disease activity and prognosis. To understand the etiology and pathogenic mechanisms of connective tissue diseases; it is particularly important to elucidate the structure and function of target autoantigens recognized by these disease-specific autoantibodies. In recent years, the nature of many target autoantigens have been identified using molecular biology approaches. Most of them are intracellular enzymes and regulatory factors necessary for important biological function involved in gene replication, transcription, RNA processing and protein translation. Thus, the studies of autoantibodies are useful not only in clinical medicine but also in basic cellular and molecular biology.  (+info)

Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. (8/296)

OBJECTIVES: To investigate whether a home exercise programme could safely be performed by patients with stable, inactive polymyositis (PM) and dermatomyositis (DM), regarding disease activity, muscle function, health status and pain. METHODS: Ten patients with reduced muscle function completed the study. A home exercise programme including exercises for strength in the upper and lower limbs, neck and trunk, for mobility in the upper limbs and moderate stretching was developed. The patients exercised for 15 min and took a 15 min walk 5 days a week during a 12 week period. Assessments included clinical evaluation of disease activity, serum creatinine phosphokinase (CPK) levels, magnetic resonance imaging (MRI) of the quadriceps, repeated muscle biopsy of the vastus lateralis, a muscle function index (FI), a walking test and a health status instrument (the SF 36) performed at the start of the study and after 12 weeks. RESULTS: After 12 weeks of exercise, there were no signs of increased disease activity as assessed clinically, by CPK values, MRI or muscle biopsy findings. On an individual basis, all patients improved regarding muscle function according to the FI, in six cases the improvement reached statistical significance (P < 0.05). A significant improvement regarding muscle function in the upper and lower limbs, walking distance and general health status was achieved. CONCLUSIONS: Our results indicate that this home exercise programme can be safely employed in patients with stable, inactive PM and DM, with beneficial effects on muscle function.  (+info)

Polymyositis is defined as a rare inflammatory disorder that causes muscle weakness and inflammation (swelling) of the muscles. It primarily affects the skeletal muscles, which are the muscles responsible for voluntary movements such as walking, talking, and swallowing. The onset of polymyositis can occur at any age but is most commonly seen in adults between 31 to 60 years old, with women being slightly more affected than men.

The exact cause of polymyositis remains unknown; however, it is believed to be an autoimmune disorder, where the body's immune system mistakenly attacks its own muscle tissue. Certain factors such as genetics, viral infections, and exposure to certain drugs may contribute to the development of this condition.

Polymyositis can cause various symptoms, including:
- Progressive muscle weakness and wasting, particularly affecting the proximal muscles (those closest to the trunk of the body) such as the hips, thighs, shoulders, and upper arms.
- Difficulty climbing stairs, lifting objects, or rising from a seated position.
- Fatigue and stiffness, especially after periods of inactivity.
- Joint pain and swelling.
- Difficulty swallowing or speaking.
- Shortness of breath due to weakened respiratory muscles.

Diagnosis of polymyositis typically involves a combination of medical history, physical examination, laboratory tests, electromyography (EMG), and muscle biopsy. Treatment usually includes medications such as corticosteroids and immunosuppressants to reduce inflammation and control the immune response. Physical therapy may also be recommended to help maintain muscle strength and flexibility.

If left untreated, polymyositis can lead to significant disability and complications, including respiratory failure, malnutrition, and cardiovascular disease. Early diagnosis and treatment are crucial for improving outcomes and preventing long-term complications.

Dermatomyositis is a medical condition characterized by inflammation and weakness in the muscles and skin. It is a type of inflammatory myopathy, which means that it causes muscle inflammation and damage. Dermatomyositis is often associated with a distinctive rash that affects the skin around the eyes, nose, mouth, fingers, and toes.

The symptoms of dermatomyositis can include:

* Progressive muscle weakness, particularly in the hips, thighs, shoulders, and neck
* Fatigue
* Difficulty swallowing or speaking
* Skin rash, which may be pink or purple and is often accompanied by itching
* Muscle pain and tenderness
* Joint pain and swelling
* Raynaud's phenomenon, a condition that affects blood flow to the fingers and toes

The exact cause of dermatomyositis is not known, but it is believed to be related to an autoimmune response in which the body's immune system mistakenly attacks healthy tissue. Treatment for dermatomyositis typically involves medications to reduce inflammation and suppress the immune system, as well as physical therapy to help maintain muscle strength and function.

Myositis is a medical term that refers to inflammation of the muscle tissue. This condition can cause various symptoms, including muscle weakness, pain, swelling, and stiffness. There are several types of myositis, such as polymyositis, dermatomyositis, and inclusion body myositis, which have different causes and characteristics.

Polymyositis is a type of myositis that affects multiple muscle groups, particularly those close to the trunk of the body. Dermatomyositis is characterized by muscle inflammation as well as a skin rash. Inclusion body myositis is a less common form of myositis that typically affects older adults and can cause both muscle weakness and wasting.

The causes of myositis vary depending on the type, but they can include autoimmune disorders, infections, medications, and other medical conditions. Treatment for myositis may involve medication to reduce inflammation, physical therapy to maintain muscle strength and flexibility, and lifestyle changes to manage symptoms and prevent complications.

Histidine-tRNA ligase is an enzyme involved in the process of protein synthesis, specifically during the step of translation. Its primary function is to catalyze the attachment of the amino acid histidine to its corresponding transfer RNA (tRNA) molecule. This enzyme does this by forming a ester bond between the carboxyl group of histidine and the 3'-hydroxyl group of the tRNA, creating a charged histidine-tRNA complex.

The histidine-tRNA ligase enzyme plays a crucial role in maintaining the accuracy of protein synthesis, as it ensures that only the correct amino acid is attached to its specific tRNA. This helps to prevent errors in the genetic code and contributes to the proper folding and functioning of proteins.

The systematic name for this enzyme is "histidine:tRNA(His) ligase (AMP-forming)" and it belongs to the family of ligases, specifically the aminoacyl-tRNA ligases. The gene that encodes this enzyme in humans is known as HARS1 (Histidyl-tRNA Synthetase 1). Defects or mutations in this gene can lead to various genetic disorders, such as histidinemia and Charcot-Marie-Tooth disease.

Interstitial lung diseases (ILDs) are a group of disorders characterized by inflammation and scarring (fibrosis) in the interstitium, the tissue and space around the air sacs (alveoli) of the lungs. The interstitium is where the blood vessels that deliver oxygen to the lungs are located. ILDs can be caused by a variety of factors, including environmental exposures, medications, connective tissue diseases, and autoimmune disorders.

The scarring and inflammation in ILDs can make it difficult for the lungs to expand and contract normally, leading to symptoms such as shortness of breath, cough, and fatigue. The scarring can also make it harder for oxygen to move from the air sacs into the bloodstream.

There are many different types of ILDs, including:

* Idiopathic pulmonary fibrosis (IPF): a type of ILD that is caused by unknown factors and tends to progress rapidly
* Hypersensitivity pneumonitis: an ILD that is caused by an allergic reaction to inhaled substances, such as mold or bird droppings
* Connective tissue diseases: ILDs can be a complication of conditions such as rheumatoid arthritis and scleroderma
* Sarcoidosis: an inflammatory disorder that can affect multiple organs, including the lungs
* Asbestosis: an ILD caused by exposure to asbestos fibers

Treatment for ILDs depends on the specific type of disease and its underlying cause. Some treatments may include corticosteroids, immunosuppressive medications, and oxygen therapy. In some cases, a lung transplant may be necessary.

Inclusion body myositis (IBM) is a rare inflammatory muscle disease characterized by progressive weakness and wasting (atrophy) of skeletal muscles. The term "inclusion body" refers to the presence of abnormal protein accumulations within muscle fibers, which are observed under a microscope during muscle biopsy. These inclusions are primarily composed of aggregated forms of amyloid-β and tau proteins, similar to those found in neurodegenerative disorders like Alzheimer's disease.

IBM typically affects individuals over 50 years old, and it is more common in men than women. The disease usually starts with weakness in the wrist and finger flexors, making it difficult to perform tasks such as gripping, buttoning shirts, or lifting objects. Over time, the weakness spreads to other muscle groups, including the thigh muscles (quadriceps), resulting in difficulty climbing stairs or rising from a seated position.

The exact cause of inclusion body myositis remains unclear; however, both immune-mediated and degenerative mechanisms are believed to contribute to its pathogenesis. Currently, there is no cure for IBM, and treatment options are primarily aimed at managing symptoms and improving quality of life. Immunosuppressive medications may be used to target the inflammatory component of the disease; however, their efficacy varies among patients. Physical therapy and exercise programs can help maintain muscle strength and function as much as possible.

Prednisolone is a synthetic glucocorticoid drug, which is a class of steroid hormones. It is commonly used in the treatment of various inflammatory and autoimmune conditions due to its potent anti-inflammatory and immunosuppressive effects. Prednisolone works by binding to specific receptors in cells, leading to changes in gene expression that reduce the production of substances involved in inflammation, such as cytokines and prostaglandins.

Prednisolone is available in various forms, including tablets, syrups, and injectable solutions. It can be used to treat a wide range of medical conditions, including asthma, rheumatoid arthritis, inflammatory bowel disease, allergies, skin conditions, and certain types of cancer.

Like other steroid medications, prednisolone can have significant side effects if used in high doses or for long periods of time. These may include weight gain, mood changes, increased risk of infections, osteoporosis, diabetes, and adrenal suppression. As a result, the use of prednisolone should be closely monitored by a healthcare professional to ensure that its benefits outweigh its risks.

Muscular diseases, also known as myopathies, refer to a group of conditions that affect the functionality and health of muscle tissue. These diseases can be inherited or acquired and may result from inflammation, infection, injury, or degenerative processes. They can cause symptoms such as weakness, stiffness, cramping, spasms, wasting, and loss of muscle function.

Examples of muscular diseases include:

1. Duchenne Muscular Dystrophy (DMD): A genetic disorder that results in progressive muscle weakness and degeneration due to a lack of dystrophin protein.
2. Myasthenia Gravis: An autoimmune disease that causes muscle weakness and fatigue, typically affecting the eyes and face, throat, and limbs.
3. Inclusion Body Myositis (IBM): A progressive muscle disorder characterized by muscle inflammation and wasting, typically affecting older adults.
4. Polymyositis: An inflammatory myopathy that causes muscle weakness and inflammation throughout the body.
5. Metabolic Myopathies: A group of inherited disorders that affect muscle metabolism, leading to exercise intolerance, muscle weakness, and other symptoms.
6. Muscular Dystonias: Involuntary muscle contractions and spasms that can cause abnormal postures or movements.

It is important to note that muscular diseases can have a significant impact on an individual's quality of life, mobility, and overall health. Proper diagnosis and treatment are crucial for managing symptoms and improving outcomes.

Autoantibodies are defined as antibodies that are produced by the immune system and target the body's own cells, tissues, or organs. These antibodies mistakenly identify certain proteins or molecules in the body as foreign invaders and attack them, leading to an autoimmune response. Autoantibodies can be found in various autoimmune diseases such as rheumatoid arthritis, lupus, and thyroiditis. The presence of autoantibodies can also be used as a diagnostic marker for certain conditions.

Paraneoplastic syndromes refer to a group of rare disorders that are caused by an abnormal immune system response to a cancerous (malignant) tumor. These syndromes are characterized by symptoms or signs that do not result directly from the growth of the tumor itself, but rather from substances produced by the tumor or the body's immune system in response to the tumor.

Paraneoplastic syndromes can affect various organs and systems in the body, including the nervous system, endocrine system, skin, and joints. Examples of paraneoplastic syndromes include Lambert-Eaton myasthenic syndrome (LEMS), which affects nerve function and causes muscle weakness; cerebellar degeneration, which can cause difficulty with coordination and balance; and dermatomyositis, which is an inflammatory condition that affects the skin and muscles.

Paraneoplastic syndromes can occur in association with a variety of different types of cancer, including lung cancer, breast cancer, ovarian cancer, and lymphoma. Treatment typically involves addressing the underlying cancer, as well as managing the symptoms of the paraneoplastic syndrome.

Creatine kinase (CK) is a muscle enzyme that is normally present in small amounts in the blood. It is primarily found in tissues that require a lot of energy, such as the heart, brain, and skeletal muscles. When these tissues are damaged or injured, CK is released into the bloodstream, causing the levels to rise.

Creatine kinase exists in several forms, known as isoenzymes, which can be measured in the blood to help identify the location of tissue damage. The three main isoenzymes are:

1. CK-MM: Found primarily in skeletal muscle
2. CK-MB: Found primarily in heart muscle
3. CK-BB: Found primarily in the brain

Elevated levels of creatine kinase, particularly CK-MB, can indicate damage to the heart muscle, such as occurs with a heart attack. Similarly, elevated levels of CK-BB may suggest brain injury or disease. Overall, measuring creatine kinase levels is a useful diagnostic tool for assessing tissue damage and determining the severity of injuries or illnesses.

A muscle is a soft tissue in our body that contracts to produce force and motion. It is composed mainly of specialized cells called muscle fibers, which are bound together by connective tissue. There are three types of muscles: skeletal (voluntary), smooth (involuntary), and cardiac. Skeletal muscles attach to bones and help in movement, while smooth muscles are found within the walls of organs and blood vessels, helping with functions like digestion and circulation. Cardiac muscle is the specific type that makes up the heart, allowing it to pump blood throughout the body.

Connective tissue diseases (CTDs) are a group of disorders that involve the abnormal production and accumulation of abnormal connective tissues in various parts of the body. Connective tissues are the structural materials that support and bind other tissues and organs together. They include tendons, ligaments, cartilage, fat, and the material that fills the spaces between cells, called the extracellular matrix.

Connective tissue diseases can affect many different systems in the body, including the skin, joints, muscles, lungs, kidneys, gastrointestinal tract, and blood vessels. Some CTDs are autoimmune disorders, meaning that the immune system mistakenly attacks healthy connective tissues. Others may be caused by genetic mutations or environmental factors.

Some examples of connective tissue diseases include:

* Systemic lupus erythematosus (SLE)
* Rheumatoid arthritis (RA)
* Scleroderma
* Dermatomyositis/Polymyositis
* Mixed Connective Tissue Disease (MCTD)
* Sjogren's syndrome
* Ehlers-Danlos syndrome
* Marfan syndrome
* Osteogenesis imperfecta

The specific symptoms and treatment of connective tissue diseases vary depending on the type and severity of the condition. Treatment may include medications to reduce inflammation, suppress the immune system, or manage pain. In some cases, surgery may be necessary to repair or replace damaged tissues or organs.

Skeletal muscle, also known as striated or voluntary muscle, is a type of muscle that is attached to bones by tendons or aponeuroses and functions to produce movements and support the posture of the body. It is composed of long, multinucleated fibers that are arranged in parallel bundles and are characterized by alternating light and dark bands, giving them a striped appearance under a microscope. Skeletal muscle is under voluntary control, meaning that it is consciously activated through signals from the nervous system. It is responsible for activities such as walking, running, jumping, and lifting objects.

Systemic Scleroderma, also known as Systemic Sclerosis (SSc), is a rare, chronic autoimmune disease that involves the abnormal growth and accumulation of collagen in various connective tissues, blood vessels, and organs throughout the body. This excessive collagen production leads to fibrosis or scarring, which can cause thickening, hardening, and tightening of the skin and damage to internal organs such as the heart, lungs, kidneys, and gastrointestinal tract.

Systemic Scleroderma is characterized by two main features: small blood vessel abnormalities (Raynaud's phenomenon) and fibrosis. The disease can be further classified into two subsets based on the extent of skin involvement: limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc).

Limited cutaneous systemic sclerosis affects the skin distally, typically involving fingers, hands, forearms, feet, lower legs, and face. It is often associated with Raynaud's phenomenon, calcinosis, telangiectasias, and pulmonary arterial hypertension.

Diffuse cutaneous systemic sclerosis involves more extensive skin thickening and fibrosis that spreads proximally to affect the trunk, upper arms, thighs, and face. It is commonly associated with internal organ involvement, such as interstitial lung disease, heart disease, and kidney problems.

The exact cause of Systemic Scleroderma remains unknown; however, it is believed that genetic, environmental, and immunological factors contribute to its development. There is currently no cure for Systemic Scleroderma, but various treatments can help manage symptoms, slow disease progression, and improve quality of life.

Myoglobinuria is a medical condition characterized by the presence of myoglobin in the urine. Myoglobin is a protein found in muscle cells that is released into the bloodstream when muscle tissue is damaged or broken down, such as during intense exercise, trauma, or muscle diseases like muscular dystrophy and rhabdomyolysis.

When myoglobin is present in high concentrations in the blood, it can damage the kidneys by causing direct tubular injury, cast formation, and obstruction, which can lead to acute kidney injury (AKI) or even renal failure if left untreated. Symptoms of myoglobinuria may include dark-colored urine, muscle pain, weakness, and swelling, as well as symptoms related to AKI such as nausea, vomiting, and decreased urine output.

Diagnosis of myoglobinuria is typically made by detecting myoglobin in the urine using a dipstick test or more specific tests like immunoassays or mass spectrometry. Treatment may involve aggressive fluid resuscitation, alkalization of the urine to prevent myoglobin precipitation, and management of any underlying conditions causing muscle damage.

A nervous system autoimmune disease, experimental, refers to a type of disorder in which the immune system mistakenly attacks healthy nerves or tissues in the nervous system. This category includes conditions that are currently being researched and have not yet been fully proven or accepted by the medical community as definitive diseases.

In an autoimmune disease, the body's immune system produces antibodies and activates immune cells (such as T-cells) to attack and destroy foreign substances, such as bacteria and viruses. However, in an experimental nervous system autoimmune disease, the immune system mistakenly identifies normal nerves or nerve tissues as harmful and attacks them. This can lead to damage or destruction of the nerves, resulting in various neurological symptoms.

Examples of experimental nervous system autoimmune diseases may include conditions such as MOG antibody-associated disease (MOGAD) or anti-NMDA receptor encephalitis, which are still being studied and have not yet been fully recognized by the medical community. It is important to note that while these conditions are considered experimental, they can still cause significant harm and should be treated with appropriate medical interventions.

Autoimmune diseases are a group of disorders in which the immune system, which normally protects the body from foreign invaders like bacteria and viruses, mistakenly attacks the body's own cells and tissues. This results in inflammation and damage to various organs and tissues in the body.

In autoimmune diseases, the body produces autoantibodies that target its own proteins or cell receptors, leading to their destruction or malfunction. The exact cause of autoimmune diseases is not fully understood, but it is believed that a combination of genetic and environmental factors contribute to their development.

There are over 80 different types of autoimmune diseases, including rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, psoriasis, and inflammatory bowel disease. Symptoms can vary widely depending on the specific autoimmune disease and the organs or tissues affected. Treatment typically involves managing symptoms and suppressing the immune system to prevent further damage.

Mediastinal emphysema is a medical condition characterized by the presence of air or gas within the mediastinum, which is the central compartment of the thorax that contains the heart, esophagus, trachea, bronchi, thymus gland, and other associated structures.

In mediastinal emphysema, the air accumulates in the mediastinal tissues and spaces, leading to their abnormal distention or swelling. This condition can result from various causes, including:

* Pulmonary trauma or barotrauma (e.g., mechanical ventilation, scuba diving)
* Infections that cause gas-forming organisms (e.g., pneumomediastinum)
* Air leakage from the lungs or airways (e.g., bronchial rupture, esophageal perforation)
* Certain medical procedures (e.g., mediastinoscopy, tracheostomy)

Mediastinal emphysema can cause symptoms such as chest pain, cough, difficulty breathing, and swallowing problems. In severe cases, it may lead to life-threatening complications, including tension pneumothorax or mediastinitis. Treatment depends on the underlying cause and severity of the condition.

Antinuclear antibodies (ANA) are a type of autoantibody that target structures found in the nucleus of a cell. These antibodies are produced by the immune system and attack the body's own cells and tissues, leading to inflammation and damage. The presence of ANA is often used as a marker for certain autoimmune diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome, rheumatoid arthritis, scleroderma, and polymyositis.

ANA can be detected through a blood test called the antinuclear antibody test. A positive result indicates the presence of ANA in the blood, but it does not necessarily mean that a person has an autoimmune disease. Further testing is usually needed to confirm a diagnosis and determine the specific type of autoantibodies present.

It's important to note that ANA can also be found in healthy individuals, particularly as they age. Therefore, the test results should be interpreted in conjunction with other clinical findings and symptoms.

Muscle weakness is a condition in which muscles cannot develop the expected level of physical force or power. This results in reduced muscle function and can be caused by various factors, including nerve damage, muscle diseases, or hormonal imbalances. Muscle weakness may manifest as difficulty lifting objects, maintaining posture, or performing daily activities. It is essential to consult a healthcare professional for proper diagnosis and treatment of muscle weakness.

Muscular dystrophies are a group of genetic disorders that primarily affect skeletal muscles, causing progressive weakness and degeneration. They are characterized by the lack or deficiency of a protein called dystrophin, which is essential for maintaining the integrity of muscle fibers. The most common form is Duchenne muscular dystrophy (DMD), but there are many other types with varying symptoms and severity. Over time, muscle wasting and weakness can lead to disability and shortened lifespan, depending on the type and progression of the disease. Treatment typically focuses on managing symptoms, maintaining mobility, and supporting quality of life.

Immunosuppressive agents are medications that decrease the activity of the immune system. They are often used to prevent the rejection of transplanted organs and to treat autoimmune diseases, where the immune system mistakenly attacks the body's own tissues. These drugs work by interfering with the immune system's normal responses, which helps to reduce inflammation and damage to tissues. However, because they suppress the immune system, people who take immunosuppressive agents are at increased risk for infections and other complications. Examples of immunosuppressive agents include corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus.

Mixed Connective Tissue Disease (MCTD) is a rare overlapping condition of the connective tissues, characterized by the presence of specific autoantibodies against a protein called "U1-snRNP" or "U1-small nuclear ribonucleoprotein." This disorder has features of various connective tissue diseases such as systemic lupus erythematosus (SLE), scleroderma, polymyositis, and rheumatoid arthritis. Symptoms may include swollen hands, joint pain and swelling, muscle weakness, skin thickening, lung involvement, and Raynaud's phenomenon. The exact cause of MCTD is unknown, but it is believed to involve both genetic and environmental factors leading to an autoimmune response. Early diagnosis and treatment are essential for better disease management and preventing severe complications.

The hallmark of polymyositis is weakness and/or loss of muscle mass in the proximal musculature, as well as flexion of the neck ... Polymyositis tends to become evident in adulthood, presenting with bilateral proximal muscle weakness often noted in the upper ... Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and ... Foot drop in one or both feet can be a symptom of advanced polymyositis and inclusion body myositis. The systemic involvement ...
... polymyositis (PM); anti-synthetase syndrome; and, occasionally, Sjögren syndrome can coexist and overlap. The course of the ...
Velázquez has battled polymyositis. https://prpop.org/biografias/rosita-velazquez/ Reconocen la trayectoria ininterrumpida de ...
M33.2) Polymyositis produces muscle weakness. It can often be treated by drugs like corticosteroids or immunosuppressants. ... polymyositis (rarely) Infectious myopathies Endocrine and metabolic disorders - hypokalemia, hypocalcemia, hypercalcemia Onset ... in adulthood Inflammatory myopathies - polymyositis, dermatomyositis, inclusion body myositis, viral (HIV) Infectious ...
Polymyositis: a rare inflammatory disease that causes muscle weakness affecting both sides of your body. Dermatomyositis: an ... People with scleroderma overlap syndrome have symptoms of both systemic scleroderma and/or polymyositis and dermatomyositis: ... Jablonska S.; Blaszczyk M. (1998). "Scleromyositis: a scleroderma/polymyositis overlap syndrome". Clinical Rheumatology. 17 (6 ... People with scleromyositis have symptoms of both systemic scleroderma and either polymyositis or dermatomyositis, and is ...
Jablonska, S; Blaszczyk, M (1998). "Scleromyositis: a scleroderma/polymyositis overlap syndrome". Clinical Rheumatology. 17 (6 ... polymyositis, or dermatomyositis alone. As the autobodies are found mainly in patients that have characteristics of several ... "PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome". Arthritis & Rheumatism. 50 ( ... an autoimmune disease in which patients have symptoms from both scleroderma and either polymyositis or dermatomyositis. ...
Holton JL, Wedderburn LR, Hanna MG (29 May 2013). "Polymyositis, Dermatomyositis and Inclusion Body Myositis". In Goebel HH, ... Cited in: Holton JL, Wedderburn LR, Hanna MG (29 May 2013). "Polymyositis, Dermatomyositis and Inclusion Body Myositis". In ... The main classes of idiopathic inflammatory myopathy are polymyositis (PM), dermatomyositis (DM) (including juvenile, ...
... polymyositis, and eosinophilia". Muscle & Nerve. 13 (5): 385-395. doi:10.1002/mus.880130505. ISSN 0148-639X. PMID 2189069. ...
Danieli, MG; Gelardi, C; Guerra, F; Cardinaletti, P; Pedini, V; Gabrielli, A (May 2016). "Cardiac involvement in polymyositis ... and Bohan, Anthony; Peter, James B. (20 February 1975). "Polymyositis and Dermatomyositis: (Second of Two Parts)". New England ... It has also been classified as an idiopathic inflammatory myopathy, along with polymyositis, necrotizing autoimmune myositis, ... Bohan, Anthony; Peter, James B. (13 February 1975). "Polymyositis and Dermatomyositis: (First of Two Parts)". New England ...
In December 2006, Downing suffered from polymyositis. Despite the debilitating aspects of the disease, he worked towards ...
IBM is often confused with (misdiagnosed as) polymyositis. Polymyositis that does not respond to treatment is likely IBM. ... but exhibits a skin rash not seen in polymyositis or sIBM. It may have different root causes unrelated to either polymyositis ... sIBM weakness comes on over months or years and progresses steadily, whereas polymyositis has an onset of weeks or months. ... IBM is often initially misdiagnosed as polymyositis. A course of prednisone is typically completed with no improvement and ...
High troponin T levels have also been reported in patients with inflammatory muscle diseases such as polymyositis or ... Kobayashi S, Tanaka M, Tamura N, Hashimoto H, Hirose S (September 1992). "Serum cardiac troponin T in polymyositis/ ... April 2001). "Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis ...
de Rooij DJ, Van de Putte LB, Habets WJ, Van Venrooij WJ (1989). "Marker antibodies in scleroderma and polymyositis: clinical ...
Robert Erickson, 80, American composer and author, polymyositis. Felice Ippolito, 81, Italian geologist and politician. Bill ...
Sasaki H, Kohsaka H (November 2018). "Current diagnosis and treatment of polymyositis and dermatomyositis". Modern Rheumatology ... polymyositis, and inclusion body myositis. Other autoimmune diseases, such as systemic lupus erythematosus, can also cause ...
The most common antibody is "Anti-Jo-1" named after John P, a patient with polymyositis and interstitial lung disease detected ... Nishikai M, Reichlin M (1980). "Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis". Arthritis Rheum ...
Safety of a home exercise programme in patients with polymyositis and dermatomyositis: A pilot study. Rheumatology. 38, 608-611 ... Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. British ... Inclusion Body Myositis Masquerading as Polymyositis: A Case Study. Archives of Physical Medicine and Rehabilitation. 81:1123- ... Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. Journal of Rheumatology. 20:1340-1344. Wiesinger GF, ...
de Rooij DJ, Van de Putte LB, Habets WJ, Van Venrooij WJ (1989). "Marker antibodies in scleroderma and polymyositis: clinical ...
The latter category includes polymyositis and other muscle disorders. Muscle fatigue may be due to precise molecular changes ...
Ali, A (2006). "Tropical spastic paraparesis and polymyositis: a still unfolding story". West Indian Medical Journal. 55 (6): ... polymyositis (an inflammatory muscle disease), keratoconjunctivitis sicca (persistent dryness of the cornea and conjunctiva), ...
Scleroderma, polymyositis, and dermatomyositis elicit little or no CRP response.[citation needed] CRP levels also tend not to ...
Wright died from polymyositis in Cambridge, Massachusetts, at age 70. He is buried in Holyhood Cemetery in Brookline, ...
Schubert, Walter (2002). "Polymyositis, Topological Proteomics Technology and Paradigm for Cell Invasion Dynamics". Journal of ...
... heart failure due to polymyositis. Brian Eatwell, 67, British production designer (The Man Who Fell to Earth, The Three ...
Retrieved 2016-04-24.{{cite web}}: CS1 maint: multiple names: authors list (link) Polymyositis at eMedicine MedlinePlus ... Polymyositis is an autoimmune condition in which the muscle is affected. Rhabdomyolysis is the breakdown of muscular tissue due ...
... died of polymyositis in Bristol on 8 September 2020. At the time of her death, Mason had written three short novels ...
... died from Polymyositis in Michigan on May 3, 2013. Dillon, Merton Lynn (1961). Elijah P. Lovejoy: Abolitionist ...
... is a family of myositis disorders that includes polymyositis and dermatomyositis. As such, it includes both ...
Yoga foot drop Toe walking Polymyositis inclusion body myositis Chisholm, Amanda E.; Perry, Stephen D.; McIlroy, William E. ( ...
ISBN 0-9757919-2-3[page needed] Clark DW, Strandell J (June 2006). "Myopathy including polymyositis: a likely class adverse ...
The hallmark of polymyositis is weakness and/or loss of muscle mass in the proximal musculature, as well as flexion of the neck ... Polymyositis tends to become evident in adulthood, presenting with bilateral proximal muscle weakness often noted in the upper ... Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and ... Foot drop in one or both feet can be a symptom of advanced polymyositis and inclusion body myositis. The systemic involvement ...
... presents with predominant or isolated proximal upper limb and neck weakness. It has marked female ... Cervicobrachial polymyositis J Clin Neuromuscul Dis. 2014 Dec;16(2):59-68. doi: 10.1097/CND.0000000000000059. ... Conclusions: Cervicobrachial polymyositis presents with predominant or isolated proximal upper limb and neck weakness. It has ... Bohan and Peter and Targoff criteria were used for the diagnosis of polymyositis. The study period was of 14 years (from 1999 ...
Polymyositis and dermatomyositis are rare inflammatory diseases. (The condition is called dermatomyositis when it involves the ... Polymyositis and dermatomyositis are rare inflammatory diseases. (The condition is called dermatomyositis when it involves the ... Polymyositis can affect people at any age. It is most common in adults between ages 50 and 60, and in older children. It ... Polymyositis is a systemic disease. This means it affects the whole body. Muscle weakness and tenderness can be signs of ...
Clinically similar to polymyositis, dermatomyositis is an idiopathic, inflammatory myopathy associated with ... ... Polymyositis is an idiopathic inflammatory myopathy that causes symmetrical, proximal muscle weakness; elevated skeletal muscle ... Polymyositis is one of several idiopathic inflammatory myopathies. [2] Clinically similar to polymyositis, dermatomyositis is ... Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the ...
Polymyositis is a very rare idiopathic inflammatory myopathy ... Polymyositis is a diagnosis of exclusion *Polymyositis is ... M33.21 - polymyositis with respiratory involvement *M33.22 - polymyositis with myopathy *M33.29 - polymyositis with other organ ... Polymyositis. Authors: Ashley M. Holloman, M.D., Carrie A. Mohila, M.D., Ph.D. ... Existence of polymyositis as a distinct entity has been questioned and may not be included in some idiopathic inflammatory ...
Current topic: Polymyositis and Dermatomyositis: Care Instructions Create your printer-friendly document by clicking topic ...
... J Rheumatol. 1995 Apr;22(4):668-74. ... Objective: The establishment of classification criteria for polymyositis (PM) and dermatomyositis (DM). ...
Polymyositis. May 2, 2022. May 2, 2022. Dr. Meenakshi Chauhan Alternative Treatment For Polymyositis With Herbal Remedies ...
... isolated polymyositis (polymyositis with endomysial cell infiltrates), n = 9 (5%); dermatomyositis, n = 59 (36%; 54 isolated, 3 ... Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol1994;21:643-8. ... Background: Although polymyositis and dermatomyositis are regarded as treatable disorders, prognosis is not well known, as in ... Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a ...
Acute fulminant myoglobinuric polymyositis with picornavirus-like crystals. Message subject: (Your Name) has forwarded a page ...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy. ...
Read about my journey with polymyositis and how I found healing through faith and lifestyle changes. ... He told asked me " Did I ever have polymyositis? Because there was not a trace of it in my bloodwork. I immediately began to ... Hello everyone! I was diagnosed with polymyositis in 2007. 4/07 I noticed fatigue in my legs as I walked. Within two weeks, my ...
Clinically similar to polymyositis, dermatomyositis is an idiopathic, inflammatory myopathy associated with ... ... Polymyositis is an idiopathic inflammatory myopathy that causes symmetrical, proximal muscle weakness; elevated skeletal muscle ... Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the ... encoded search term (Polymyositis) and Polymyositis What to Read Next on Medscape ...
Discover potential symptoms and complications of polymyositis at 10FAQ. ... Polymyositis is an inflammatory disorder that causes bilateral muscle weakness. ... 2020, rarediseases.org/rare-diseases/polymyositis/. *6. Polymyositis. Polymyositis - Better Health Channel, www.betterhealth. ... vic.gov.au/health/ConditionsAndTreatments/polymyositis#symptoms-of-polymyositis. *7. April Chang-Miller, M.D. Polymyositis: ...
What is Polymyositis? Learn about common symptoms, coexisting conditions, and risk factors associated with this autoimmune ... Polymyositis typically occurs after the age of 20, affects more females than males, and can develop following viral infections ... Polymyositis-Symptoms and causes. (n.d.). Mayo Clinic. Retrieved June 12, 2021, from https://www.mayoclinic.org/diseases- ... Polymyositis. (n.d.-a). The Myositis Association. Retrieved June 12, 2021, from https://www.myositis.org/about-myositis/types- ...
22 Apr: What is Polymyositis?. Polymyositis is a rare autoimmune disease that affects the muscles in the body, causing ...
Myositis - Polymyositis, dermatomyositis, CTD associated myositis and undifferentiated inflammatory myositis. Red flags. ... Myositis - Polymyositis, dermatomyositis, CTD associated myositis and undifferentiated inflammatory myositis ... New onset and/or active myositis including polymyositis, dermatomyositis. Connected Tissue disease associated myositis and ...
Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series ... for the treatment of severe steroid-refractory esophageal involvement related to polymyositis/dermatomyositis (PM/DM).. METHODS ...
Polymyositis. Polymyositis (PM) begins with muscle weakness in the muscles closest to the trunk of the body and then expands ...
Polymyositis & Dermatomyositis & boost your knowledge! Study for your classes, USMLE, MCAT or MBBS. Learn online with high- ... Polymyositis Polymyositis (PM) is an autoimmune inflammatory myopathy caused by T cell-mediated muscle injury. The etiology of ... Polymyositis is most common in middle-aged women and rarely affects children. Patients present with progressive and symmetric ... The lecture Inflammatory Myopathies, Polymyositis & Dermatomyositis by Carlo Raj, MD is from the course Connective Tissue ...
Polymyositis List of Fatal Autoimmune Diseases. April 3, 2023. April 3, 2023. Jung Sammie ...
Pronunciation of polymyositis with 2 audio pronunciations, 1 synonym, 2 meanings, 10 translations and more for polymyositis. ... Learn more about the word polymyositis , its origin, alternative forms, and usage from Wiktionary. Quiz on polymyositis. {{ ... Keep up. Oops! Seems like your pronunciation of polymyositis is not correct. You can try again. Original audio Your audio ... Keep up. Oops! Seems like your pronunciation of polymyositis is not correct. You can try again. Original audio Your audio ...
Polymyositis is an inflammatory disease that affects the muscles and surrounding tissues, including blood vessels. It is a rare ... Diagnosis of Polymyositis. A diagnosis of polymyositis is made based on a review of the reported symptoms, family medical ... Causes of Polymyositis. Polymyositis has no clear cause and is not fully understood. While not a genetic disorder, the ... Treatment of Polymyositis. Polymyositis is an extremely treatable disease, normally with drugs that suppress the immune system ...
Polymyositis Complications. A number of complications can result from severe cases of Polymyositis. These include:. *Heart ... Polymyositis Diagnosis. Diagnosing Polymyositis is a difficult process as the signs and symptoms of this condition often ... Picture 2 - Polymyositis Image. Polymyositis is an inflammatory muscle condition that affects both children and adults. It ... Polymyositis Causes. The exact factors responsible for Polymyositis are not known. However, the involvement of certain ...
Polymyositis. Polymyositis occurs more commonly in women after the second decade. It is associated with infiltration of muscle ... Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with ... Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 ... The more diffuse acquired disorders include dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM). ...
What are the diagnostic criteria for polymyositis PM?. Diagnostic criteria for Polymyositis. PM. A diagnosis of polymyositis ... What is polymyositis myositis?. Polymyositis is an inflammatory muscle disease that causes muscle weakness. Myositis means ... How do you rule out polymyositis?. If your doctor suspects you have polymyositis, he or she might suggest some of the following ... How long does it take for polymyositis to develop?. Polymyositis is one of a group of rare muscle diseases called inflammatory ...
Therapies for patients with polymyositis/dermatomyositis (PM/DM) who are resistant to steroids are limited, unproven and often ... Apheresis in the Treatment of Polymyositis/Dermatomyositis Leitman, S F. Clinical Center, United States ... Therapies for patients with polymyositis/dermatomyositis (PM/DM) who are resistant to steroids are limited, unproven and often ... Apheresis in the Treatment of Polymyositis/Dermatomyositis. Leitman, S F. / Clinical Center. ...
Dermatomyositis and Polymyositis Dermatomyositis and polymyositis are autoimmune diseases that can both cause muscle weakness. ...
Polymyositis is a rare or infrequent disease that involves the inflammation of an area of the body. Learn more about ... Polymyositis is a rare disease in which inflammation of an area of the body develops. It occurs more frequently in women and ... Polymyositis is characterized by pain in multiple muscle areas.. As a rule, this disorders systemic, i.e. it can affect any ... Polymyositis is a rare or infrequent disease that involves the inflammation of an area of the body. Learn more about ...
  • The systemic involvement of polymyositis includes interstitial lung disease (ILD) and heart disease, such as heart failure and conduction abnormalities. (wikipedia.org)
  • Polymyositis is a systemic disease. (medlineplus.gov)
  • Polymyositis is an immune-mediated syndrome secondary to defective cellular immunity that is most commonly associated with other systemic autoimmune diseases. (medscape.com)
  • Notably, these neoplasms shared significant associations with 5 ADs (immune thrombocytopenic purpura, polymyositis/dermatomyositis, rheumatoid arthritis, Sjogren syndrome and systemic lupus erythematosis). (lu.se)
  • Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and inclusion body myositis. (wikipedia.org)
  • Foot drop in one or both feet can be a symptom of advanced polymyositis and inclusion body myositis. (wikipedia.org)
  • Idiopathic inflammatory myopathies comprise a heterogeneous group of disorders, including polymyositis, dermatomyositis and sporadic inclusion body myositis (s-IBM). (bmj.com)
  • Foot drop in either or both feet, which might indicate advanced polymyositis as well as IBM (Inclusion Body Myositis). (hxbenefit.com)
  • A general term meaning inflammation of the muscles, myositis includes the following diseases: dermatomyositis, inclusion body myositis, juvenile myositis, and polymyositis. (vaccineawarenesscenter.com)
  • Exploratory Analysis of the Relationships between Aerobic Capacity and Self-Reported Fatigue in Patients with Rheumatoid Arthritis, Polymyositis, and Chronic Fatigue Syndrome. (phoenixrising.me)
  • 2016 American College of Rheumatology/European League against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative. (medlineplus.gov)
  • Dermatomyositis and polymyositis are autoimmune diseases that can both cause muscle weakness. (livestrong.com)
  • I knew there was dermatomyositis and polymyositis. (medscape.com)
  • Dermatomyositis and polymyositis are related topics. (limamemorial.org)
  • The inflammation of polymyositis is mainly found in the endomysial layer of skeletal muscle, whereas dermatomyositis is characterized primarily by inflammation of the perimysial layer of skeletal muscles. (wikipedia.org)
  • Polymyositis is a rare autoimmune disease that affects the muscles in the body, causing inflammation and muscle weakness. (sicknotdead.com)
  • Polymyositis is one of a group of rare muscle diseases called inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness. (farfromhomemovie.com)
  • Polymyositis is a rare or infrequent disease that involves the inflammation of an area of the body. (steptohealth.com)
  • Polymyositis causes muscle weakness and inflammation in adults. (myositis.org.uk)
  • While defined as an inflammation of the muscle, polymyositis can also be a feature of a more general autoimmune illness. (myositis.org.uk)
  • Active irritative myopathy was found in 93% (13/14) patients on needle electromyography studies, and all patients had evidence of inflammatory myopathy (polymyositis) on muscle biopsy. (nih.gov)
  • [ 2 ] Clinically similar to polymyositis, dermatomyositis is an idiopathic inflammatory myopathy associated with characteristic dermatologic manifestations. (medscape.com)
  • Alternative Treatment For Polymyositis With Herbal Remedies Abstract The disease is also known as myopathy. (planetayurveda.com)
  • Granulomatous myopathy: its relationship to sarcoidosis and polymyositis. (bmj.com)
  • 5. Polymyositis and Necrotizing Myopathy. (10faq.com)
  • Polymyositis (PM) is an autoimmune inflammatory myopathy caused by T cell-mediated muscle injury. (lecturio.com)
  • citation needed] Polymyositis and the associated inflammatory myopathies have an associated increased risk of cancer. (wikipedia.org)
  • Polymyositis is one of several idiopathic inflammatory myopathies. (medscape.com)
  • Polymyositis is part of a group of muscle diseases called inflammatory myopathies. (10faq.com)
  • The lecture Inflammatory Myopathies, Polymyositis & Dermatomyositis by Carlo Raj, MD is from the course Connective Tissue Diseases. (lecturio.com)
  • 2. 'Polymyositis: Symptoms, Causes & Treatments. (10faq.com)
  • The first symptoms of polymyositis usually appear between the ages of 30 to 50, although they can occur at any age. (10faq.com)
  • A diagnosis of polymyositis is made based on a review of the reported symptoms, family medical history, a physical examination, and most often lab tests and a muscle biopsy. (healthsoul.com)
  • Diagnosing Polymyositis is a difficult process as the signs and symptoms of this condition often overlap with certain other diseases and related conditions. (hxbenefit.com)
  • There are numerous health conditions that show signs and symptoms similar to that of Polymyositis, making it difficult to reach a conclusive diagnosis. (hxbenefit.com)
  • What are the first symptoms of polymyositis? (farfromhomemovie.com)
  • PM. A diagnosis of polymyositis should be considered for patients presenting with no skin symptoms and four of the following criteria: Symmetrical muscle weakness in the shoulders/upper arms or hips/upper legs and trunk. (farfromhomemovie.com)
  • There is no cure for polymyositis, but treatment can help to improve symptoms and quality of life. (carosp.com)
  • A few key signs and symptoms can help you know if you have polymyositis. (carosp.com)
  • There is no one definite cure for polymyositis as of now, but treatment can help to reduce symptoms and improve quality of life. (carosp.com)
  • Bohan and Peter and Targoff criteria were used for the diagnosis of polymyositis. (nih.gov)
  • Because of the pattern of weakness, cervicobrachial polymyositis tends to be confused with other common neurological conditions having upper girdle weakness, leading to delay in the diagnosis of this potentially treatable condition. (nih.gov)
  • What are the four characteristic criteria for the diagnosis of polymyositis? (farfromhomemovie.com)
  • When to suspect the diagnosis - The diagnosis of dermatomyositis (DM) or polymyositis (PM) should be suspected in patients who present with proximal muscle weakness. (farfromhomemovie.com)
  • Polymyositis is a severe condition that can lead to disability, so early diagnosis and treatment are essential. (carosp.com)
  • Diagnosis of polymyositis (PM) (including antisynthetase syndrome (ASyS)) c. (who.int)
  • While there is no cure for polymyositis, treatment - ranging from medications to physical therapy - can improve your muscle strength and function. (farfromhomemovie.com)
  • The hallmark of polymyositis is weakness and/or loss of muscle mass in the proximal musculature, as well as flexion of the neck and torso. (wikipedia.org)
  • Polymyositis tends to become evident in adulthood, presenting with bilateral proximal muscle weakness often noted in the upper legs due to early fatigue while walking. (wikipedia.org)
  • To characterize and analyze a subgroup of patients with polymyositis presented with predominant or isolated proximal upper limb and neck weakness. (nih.gov)
  • Patients with polymyositis, presenting with predominant or isolated weakness of upper limbs and the neck, were included. (nih.gov)
  • Cervicobrachial polymyositis presents with predominant or isolated proximal upper limb and neck weakness. (nih.gov)
  • Muscle weakness and tenderness can be signs of polymyositis. (medlineplus.gov)
  • Muscle weakness is the most recognizable symptom of polymyositis. (10faq.com)
  • Polymyositis (PM) begins with muscle weakness in the muscles closest to the trunk of the body and then expands from there. (healthline.com)
  • The muscle weakness associated with polymyositis involves the muscles closest to the trunk, such as those in your hips, thighs, shoulders, upper arms and neck. (farfromhomemovie.com)
  • Meanwhile, complications from polymyositis may result from severe and progressive muscle weakness or complications such as cardiac or pulmonary involvement. (carosp.com)
  • Polymyositis is a rare inflammatory muscle disease that can cause muscle weakness and disability. (carosp.com)
  • This randomized, controlled study on patients with polymyositis or dermatomyositis was based on three hypotheses: patients display impaired endurance due to reduced aerobic capacity and muscle weakness, endurance training improves their exercise performance by increasing the aerobic capacity, and endurance training has general beneficial effects on their health status. (biomedcentral.com)
  • Polymyositis and dermatomyositis are rare inflammatory diseases. (medlineplus.gov)
  • Polymyositis, dermatomyositis, and juvenile myositis are all autoimmune diseases, meaning the body's immune system is attacking the muscle. (vaccineawarenesscenter.com)
  • Neutrophil-to-lymphocyte ratio (NLR) is increased and associated with overall survival (OS) in inflammatory diseases including dermatomyositis/polymyositis (DM/PM) and many cancers. (univ-tours.fr)
  • A nerve conduction velocity test and electromyography (EMG) examination are electrical tests that allow detection of any muscle abnormalities that are typical of Polymyositis and exclude other nerve-muscle disorders. (hxbenefit.com)
  • To assess the long-term outcome of esophageal complications in the group of patients receiving intravenous immunoglobulins (IVIG) for the treatment of severe steroid-refractory esophageal involvement related to polymyositis/dermatomyositis (PM/DM). (qxmd.com)
  • Acute fulminant myoglobinuric polymyositis with picornavirus-like crystals. (bmj.com)
  • People having anti-SRP antibodies are affected by acute polymyositis. (hxbenefit.com)
  • We analyzed data for 195 patients with myositis (75 with adult polymyositis [PM], 72 with adult Dermatomyositis [DM], and 48 with juvenile DM) in the Rituximab in Myositis trial. (elsevierpure.com)
  • Polymyositis affects the skeletal muscles. (medlineplus.gov)
  • Polymyositis is most common in middle-aged women and rarely affects children. (lecturio.com)
  • Polymyositis is an inflammatory disease that affects the muscles and surrounding tissues, including blood vessels. (healthsoul.com)
  • Usually, polymyositis affects the muscles that are closest to the trunk of the body. (farfromhomemovie.com)
  • Polymyositis mostly affects the muscles of the hips and thighs, the upper arms, the top part of the back, the shoulder area and the neck. (xshotpix.com)
  • The skin involvement of dermatomyositis is absent in polymyositis. (wikipedia.org)
  • Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. (qxmd.com)
  • Another common symptom of polymyositis is muscle pain. (carosp.com)
  • Although polymyositis and dermatomyositis are regarded as treatable disorders, prognosis is not well known, as in the literature long-term outcome and prognostic factors vary widely. (bmj.com)
  • People with polymyositis who also have cancer generally have a worse prognosis. (carosp.com)
  • The referring diagnoses in all 14 patients were other than polymyositis, for example, motor neuron disease, cervical radiculopathy, brachial neuritis, chronic inflammatory demyelinating polyradiculoneuropathy, anti-MuSK myasthenia gravis, and facioscapulohumeral muscular dystrophy. (nih.gov)
  • Antisynthetase syndrome may be a further complication for someone with polymyositis or dermatomyositis. (myositis.org.uk)
  • Histopathology of polymyositis showing endomysial mononuclear inflammatory infiltrate and muscle fiber necrosis. (medscape.com)
  • To analyse the prognostic outcome factors in polymyositis and adult dermatomyositis. (bmj.com)
  • In this study, we assessed the long-term outcome of a large group of adult patients with polymyositis and dermatomyositis, including survival, development of associated disorders, clinical condition and course, and prognostic factors. (bmj.com)
  • People affected by polymyositis may struggle to climb stairs, get up out of a chair, lift objects or raise their arms above their heads. (10faq.com)
  • With early treatment, a person with polymyositis can go into remission. (carosp.com)
  • Polymyositis is a rare chronic inflammatory muscle disease that occurs when the body's immune system attacks healthy muscle tissue. (carosp.com)
  • An autoimmune response to nuclear and cytoplasmic autoantigens is detected in about 60-80% of patients with polymyositis and dermatomyositis. (medscape.com)
  • MSAs are found in approximately 40% of patients with polymyositis or dermatomyositis, whereas MAAs are found in 20-50% of these patients. (medscape.com)
  • In most studies on outcome in polymyositis and dermatomyositis, diagnostic criteria did not specifically exclude patients with s-IBM, 1, 3- 7, 10, 11, 14, 15 which can easily be misdiagnosed as polymyositis. (bmj.com)
  • Patients with polymyositis should be educated early about the disease and should be provided with realistic expectations about outcomes. (medscape.com)
  • In Polymyositis patients, an unknown cause might send a signal to the immune system to produce autoimmune antibodies that attacks the own tissues of the body. (hxbenefit.com)
  • Therapies for patients with polymyositis/dermatomyositis (PM/DM) who are resistant to steroids are limited, unproven and often toxic. (grantome.com)
  • We conclude that plasma exchange and leukapheresis as used in this study were no more effective than sham apheresis as treatment for patients with steroid- resistant polymyositis/dermatomyositis. (grantome.com)
  • That CFS even made it into a study with RA and polymyositis patients is something of a breakthrough. (phoenixrising.me)
  • In the first part of this study, we compared 23 patients with polymyositis or dermatomyositis with 12 age- and gender-matched healthy controls. (biomedcentral.com)
  • Polymyositis and dermatomyositis patients have impaired endurance, which could be improved by 12 weeks of endurance training. (biomedcentral.com)
  • The results emphasize the importance of endurance exercise in addition to immunosuppressive treatment of patients with polymyositis or dermatomyositis. (biomedcentral.com)
  • The pathogenesis of polymyositis points toward a T-cell-mediated cytotoxic process directed against unidentified muscle antigens. (medscape.com)
  • Studies so far have yielded less favorable results than treatment for polymyositis and dermatomyositis. (medscape.com)
  • Is there a cure or treatment for polymyositis? (farfromhomemovie.com)
  • Polymyositis and dermatomyositis have many shared clinical features. (medscape.com)
  • Multiple clinical and serologic subtypes of polymyositis are now well defined, and they all have different features and prognoses. (medscape.com)
  • Polymyositis is a similar inflammatory condition, that also involves. (limamemorial.org)